A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy

RW Dal Negro, S Tognella, L Pradelli - Journal of Asthma, 2012 - Taylor & Francis
Objective. Omalizumab is a biological treatment for difficult-to-treat allergic asthma. Its
mechanism of action relies on impeding the binding of immunoglobulin E (IgE) to specific …
被引用次数：49 相关文章

A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy.

RW Dal Negro, S Tognella, L Pradelli - The Journal of Asthma …, 2012 - europepmc.org
Objective Omalizumab is a biological treatment for difficult-to-treat allergic asthma. Its
mechanism of action relies on impeding the binding of immunoglobulin E (IgE) to specific …

A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy

RW Dal Negro, S Tognella… - The Journal of asthma …, 2012 - pubmed.ncbi.nlm.nih.gov
Objective Omalizumab is a biological treatment for difficult-to-treat allergic asthma. Its
mechanism of action relies on impeding the binding of immunoglobulin E (IgE) to specific …